Peritoneal dissemination is the most common metastatic pattern in advanced gastric cancer (GC) and has a very poor prognosis. However, its molecular mechanism has not been elucidated. Our study investigated genes associated with peritoneal dissemination of GC. We performed combined expression analysis of metastatic GC cell lines and identified Procollagenlysine, 2-oxoglutarate 5-dioxygenase2 (PLOD2) as a potential regulator of peritoneal dissemination. PLOD2 is regulated by hypoxia-inducible factor-1 (HIF-1) and mediates extracellular matrix remodeling, alignment, and mechanical properties. We analyzed PLOD2 expression immunohistochemically in 179 clinical samples, and found high PLOD2 expression to be significantly associated with peritoneal dissemination, leading to poor prognosis. In an in vivo-collected metastatic cell line, downregulation of PLOD2 by siRNA reduced invasiveness and migration. Hypoxia upregulated PLOD2 mediated by HIF-1, and promoted invasiveness and migration. After exposure to hypoxia, a cell line transfected with siPLOD2 exhibited significantly suppressed invasiveness and migration, despite high HIF-1 expression. These findings indicate that PLOD2 is a regulator of, and candidate therapeutic target for peritoneal dissemination of GC. Although peritoneal dissemination of GC has a very poor prognosis, its molecular mechanism has not been elucidated. We identified PLOD2 regulated by HIF-1 as a potential regulator of peritoneal dissemination of GC. Finally, we showed that PLOD2 promotes cell invasiveness and migration in GC under hypoxia and lead to peritoneal dissemination of GC.
Introduction
Gastric cancer (GC) is the fifth-most common diagnosed cancer and the third-leading cause of cancer associated deaths worldwide, with especially high incidence in East Asia. 1 Peritoneal dissemination, a pattern of invasiveness and metastasis, is the most frequent cause of death in patients with advanced GC, and is therefore considered to portend poor prognosis in these patients. 2 However, the mechanisms of peritoneal dissemination in GC are unknown.
Various oncoproteins reportedly contribute to peritoneal dissemination of GC, 3 which respectively affect angiogenesis, 4 survival in the microenvironment 5 and epithelial-mesenchymal transition (EMT). 6 Hypoxia and hypoxia-inducible factor-1 and -2 (HIF-1 and HIF-2) have been studied as promoters of metastasis in various tumors. 7 Intratumoral hypoxia is associated with disorganized vascular networks, with intercapillary distances that are greater than the diffusion distance of oxygen. Poor oxygenation leads to increased risk of metastasis. Cancer cells adapt to hypoxic environments by activating HIF-1 and HIF-2, 8, 9 and in turn induce expression of >1000 target genes, many of which are associated with cancer cell proliferation, invasion, migration, glucose utilization, and metabolism.
In GC, HIF-1 is reportedly critical to peritoneal dissemination development. 15 In our previous research, we analyzed combined expression in a metastatic GC cell line and created a gastricdissemination expression signature (GDES), 16 which was significantly correlated with the ECM signature. We identified a type-I collagen receptor tyrosine kinase, discoidin domain receptor 2 (DDR2) which was associated with promoting peritoneal dissemination of GC. We found increased DDR2 induced EMT, which contributed to peritoneal dissemination by promoting proliferation, invasion and migration of GC cells. The critical mechanism was promotion of local stem cells through stromal collagen fibers perpendicularly aligned to the tumor. Simultaneously, we identified a signature of several genes associated with peritoneal dissemination in a previous study (Supporting Information Table S1 ), in which we analyzed combined expression in human metastatic GC cell lines (HSC58 and 58As9) and a clinical dataset of GC patients. 17 From those data, we selected 57 genes that exhibited higher expression in metastatic cells (58As9) compared to the parental cells (HSC58), and which were significantly associated with poor prognosis in the dataset of GC patients. Based on this result, we focused on another novel gene that apparently affected peritoneal dissemination of GC: procollagen-lysine, 2-oxoglutarate 5-dioxygenase-2 (PLOD2) which was very strongly associated with poor prognosis (p 5 0.0002 for overall survival). PLOD2 is one of three lysyl hydroxylase isoforms (PLOD1, PLOD2, and PLOD3) of procollagen-lysine, 2-oxyglutarate, 5-dioxygenase. PLOD2 specifically hydroxylates lysine in the telopeptide of procollagens. 18 PLOD2 is regulated by HIF-1 expression and mediates extracellular matrix (ECM) remodeling, composition, alignment, and mechanical properties.
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Although PLOD2 expression is reportedly associated with poor prognosis in several types of cancer, [20] [21] [22] its role in GC remains unknown. In our study, to clarify the clinical significance of PLOD2 expression and its functional role in GC, we investigated the association between PLOD2 expression and GC clinicopathological characteristics. We also investigated how changes in PLOD2 expression affect malignancy of GC cell lines in vitro. Here, we show that PLOD2 promotes GC progression under hypoxia and may lead to peritoneal dissemination of GC.
Material and Method

Patients and tissue samples
Primary GC tissues were obtained from 179 patients who underwent gastric resections without preoperative treatment at Kumamoto University Hospital from April 2005 to May 2012, and treated according to the Japanese Classification of Gastric Carcinoma.
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Immunohistochemistry
Paraffin-embedded material of tissues obtained from the GC patients were cut at 4-mm thickness, deparaffinized in xylene, and rehydrated through ethanol and soaked in distilled water. Sample processing and immunohistochemistry (IHC) procedures were performed as described below. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide. The sections were incubated with diluted antibodies (PLOD2, CST#3716, 1:100), and detection was performed using enzymatic Avidin-Biotin Complex (ABC)-3, 3 0 -diaminobenzidine staining (Vectastain Elite ABC Rabbit IgG Kit; VEC PK-6101). HCC was used as positive control for PLOD2 expression. All IHC staining was independently scored by two pathologists (who were blinded to patient information), using a dual scoring system of staining extent and intensity for IHC analysis. "We scored PLOD2 expression in tumor cells according to expression level (0; no expression, 1; weak expression, 2; moderate expression, or 3; strong expression) and proportion of stained cells (0-100%). PLOD2 expression was defined the score 'expression level 3 proportion of stained cells." Immunohistochemistry of HIF-1a was incubated with primary antibody against HIF-1a (Anti-HIF-1 alpha antibody, ab51608, 1:100).
Cell lines and cell culture
The human scirrhous GC cell line HSC58 was previously established from ascitic fluid of a patient with scirrhous gastric carcinoma. 24 The 58As9 cell line was derived from HSC58 after 12 cycles of direct orthotropic transplantation to the gastric walls of BALB/c nude mice and gathering cells from the ascites. 25 
MKN45
and NUGC3 were purchased from ATCC (Manassas, VA). These cell lines were grown in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO) supplemented with 10% fetal bovine serum (FBS). The cells were maintained at 378C in a humidified atmosphere containing 5% CO 2 . Low-oxygen conditions were achieved in a Ruskinn InvivO 2 400 workstation maintained at 378C with a gas mixture containing 0.5% O 2 5% CO 2 and 94.5% N 2 .
What's new?
The invasion and spread of tumor cells in the peritoneal cavity is a leading cause of death in advanced gastric cancer (GC). Despite clear associations with poor prognosis, however, little is understood about the molecular mechanisms driving peritoneal invasion and metastasis in GC. In the present study elevated levels of procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 (PLOD2) in GC patients were associated with peritoneal dissemination and poor survival. Experiments in GC cells revealed that PLOD2 is regulated by HIF-1a, with PLOD2 induction in hypoxia associated with cell invasiveness and migration. Invasiveness and metastatic potential were suppressed after PLOD2 silencing, independent of HIF-1a.
Antibodies and siRNA transfection
Monoclonal antibodies against HIF-1a (CST#3716), PLOD2 (ab72939) were obtained from Abcam (Cambridge, MA). Monoclonal antibodies against b-actin were obtained from Cell Signaling Technology (Danvers, MA). PLOD2 expression were transiently downregulated using a predesigned Silencer Select siRNA directed against PLOD2 (s10673, s10674) and a nontargeting siRNA was as a negative control. GC cells were transfected with the annealed siRNA for 48 hr using Lipofectamine RNAimax (Thermo Fisher Scientific, Waltham, MA).
Growth assay
Cells were seeded (3,000 cells/well) in triplicate 96-wells in 100 ml medium, and the plate was incubated in a humidified incubator at 378C. Each well of the plate received 10 ml of Cell Counting Kit-8 solution (Dojindo Molecular Technologies, Kumamoto, Japan) at indicated times. Absorbance was measured at 450 nm using a microplate reader after incubating the plate for 1.5 hr.
We also assessed cell growth by counting cell numbers manually, using a hemocytometer (Bio-Rad TC20 Automated Cell Counter) every day for 5 days.
Invasion assay
BioCoat Matrigel invasion chambers were used (24-well plates, 8-mm pores; BD Biosciences, San Jose, CA) according to the manufacture's protocol. Cells (5.0 3 10 4 ) were suspended in RPMI 1640 without FBS and seeded into the upper chamber. RPMI-1640 with FBS was placed in the lower chamber. The number of cells that migrated through the membrane were counted in three microscopic fields (320 magnification) per membrane. For each group, the cultures were performed in triplicate. The average was calculated from triplicate samples and statistical analyses were performed by two-tailed t tests.
Real-time imaging of cell migration
Real-time imaging of GC cells in 6-well plates was performed. Each well was coated with 200 ml of BD Matrigel (BD Biosciences). The 6-well plates were imaged with a Keyence BZ-X700 all-in-one fluorescence microscope equipped with a CO 2 -and temperature-controlled chamber and timelapse tracking system (Keyence, Osaka, Japan). Phase contrast images were taken every 10 min for 24 hr and converted to movie files using a BZ-X Analyzer (Keyence). Cell migration analyzing was performed by the movies for cell migration with the video editing analysis software VW-H2MA (Keyence) and subsequently processed the tracking data with Microsoft Excel 2010 (Microsoft, Redmond, WA) to create x, y coordinate plots and distance measurements.
Sirius red and masson's trichrome staining
Slides were incubated with a 0.1% Sirius Red solution dissolved in aqueous saturated picric acid for 1 hr, washed in acidified water (0.5% hydrogen chloride), dehydrated and mounted with DPX Mounting. Masson's trichrome staining was conducted with potassium dichromate, weigert's iron hematoxylin, 0.75% orange G solution, 1% acetic acid, ponceau de Xylidine, 2.5% phosphotungstic acid, and aniline blue solution. Image analyses of collagen-stained sections were measured using ImageJ.
Western blotting
Cultures cells in 10-cm dishes or 6-well plates were washed twice in PBS and lysed in Extraction Buffer (Thermo Fisher Scientific) and RIPA Lysis supplemented with a protease inhibitor cocktail (Thermo Fisher Scientific). Protein samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Membranes were blocked with 5% low-fat dry milk in TBST (25 mM Tris [pH7.4], 125 mM NaCl, 0.4% Tween) and then incubated with primary antibodies, including PLOD2 (ab72939, 1:500), HIF-1a (CST #3716, 1:1000), and b-actin (CST #4967, 1:1000), which were diluted in TBST, at 48C overnight for western blotting. Signals were detected by incubation with rabbit (1:5000) secondary antibodies at room temperature for 1 hr using ECL Detection System (GE Healthcare, Little Chalfont, UK).
Real-time reverse transcription polymerase chain reaction
RNA was isolated from the cultured cells using an RNeasy Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's protocol. Expression levels of mRNA were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) using TaqMan probes (Roche), and the values were normalized to those of b-actin. All qRT-PCR reactions were run using the LightCycler 480 System II (Roche Diagnostics). All data obtained using real-time RT-PCR were from experiments performed in triplicate, and the data are shown as the mean 6 standard error (SE).
Statistical analysis
All experiments were performed in triplicate unless otherwise noted, and the data shown are representative of consistently observed results. The data are presented as the mean 6 standard deviation (SD). The Mann-Whitney U test was used to compare continuous variables between two groups. Categorical variables were compared using a v 2 test. Survival curves were constructed using the Kaplan-Meier method, and the log-rank test was used to evaluate the significance of differences. Variables that exhibited p values of <0.05 on univariate analysis for risk factors that affected OS and recurrence of peritoneal dissemination were subjected to multivariate analysis using Cox proportional hazard model or logistic regression analysis. For statistical analyses, we used the JMP (Version 10, SAS Institute). p < 0.05 was considered significant.
Results
PLOD2 expression is associated with peritoneal dissemination and collagen quantity in GC patients
First, we measured PLOD2 mRNA expression levels by qRT-PCR in 25 frozen gastric cancer tissues and matched normal mucosa. PLOD2 mRNA expression levels were significantly higher in cancer tissues than in normal mucosa (p 5 0.028, Fig. 1a) . Next, we investigated PLOD2 expression in tumors by immunohistochemical analysis of specimens from 179 GC patients who underwent curative resections. The patients were divided into two groups according to staining intensity scores; the low group (PLOD2 low, 0-9.9, n 5 105) and the high group (PLOD2 high, 10.0-90, n 5 74; dot/whisker plot, Supporting Information Fig. S1 ). PLOD2 expression was detected in the cytoplasm in GC cells (Fig. 1b) . We further analyzed the correlations between PLOD2 expression and clinicopathological features of those GC patients ( Table 1) . The PLOD2 high group had significantly more frequent peritoneal dissemination occurrence (p 5 0.012). However, PLOD2 expression was not significantly related to age, sex, tumor size, Borrmann type, histological type, tumor depth, lymph node metastasis, pathological stage, lymphatic invasion, venous invasion or stroma type. Next, we investigated collagen quantity by Sirius red staining in tumors from the same 179 patients because PLOD2 reportedly promotes metastasis by increasing collagen fiber in interstitial cancer tissue (Supporting Information Fig. S2a ). Sirius red staining showed that the PLOD2 high group had significantly larger quantities of collagen in GC tumors (p 5 0.0028) (Supporting Information Fig. S2b) . We have also confirmed amount of collagen in GC by Masson's trichrome staining and found equivalent result (Supporting Information Fig. S2a and 2c) . These findings suggest that PLOD2 promotes cancer progression though collagen hyperplasia.
PLOD2 expression is associated with prognosis in GC patients
In Kaplan-Meier analysis, the PLOD2 high group has significantly poorer overall survival (OS), cancer-specific survival and disease-free survival (DFS) compared to the PLOD2 low group (Fig. 1c) . Univariate analysis of OS identified age, sex, tumor depth, lymph node metastasis, lymphatic invasion, vascular invasion and PLOD2 expression as prognostic factors. Multivariate analysis identified tumor depth, lymph node metastasis and PLOD2 expression as independent prognostic factors for OS in these patients (Supporting Information Table S2 ). Furthermore, among 179 patients who had undergone curative surgery for GC, univariate and multivariate analyses showed tumor depth and PLOD2 expression to be significant predictive factors for peritoneal recurrence (Supporting Information Table S3 ).
Suppression of PLOD2 reduced cell invasiveness and migration
We examined the involvement of PLOD2 in tumor progression in vitro. We confirmed that PLOD2 expression was elevated in 58As9 cells (the cell line derived from HSC58), compared to the parent cell line (HSC58), using real-time qRT-PCR and western blotting (Fig. 2a) . To examine the function of PLOD2 in 58As9 cells, we silenced PLOD2 by siRNA (Fig. 2b) . Although suppression of PLOD2 did not affect cell proliferation rate (Fig. 2c) , suppression of PLOD2 significantly decreased invasiveness (Fig. 2d) and migration of 58As9 cells (Fig. 2e) . Next, we confirmed PLOD2 expression in each GC cell line, using real-time qRT-PCR and western blotting (Fig. 3a) . To confirm the difference of PLOD2 expression in each GC cell line, we also performed real-time qRT-PCR for those cell lines which had been cultured under hypoxic condition (Supporting Information Fig. S3 ). We selected MKN45, a PLOD2 high cell line, and also silenced PLOD2 in MKN45 cells (Fig. 3b) . Suppression of PLOD2 decreased invasiveness (Fig. 3d) and migration (Fig. 3e) . Those results demonstrate that PLOD2 was significantly associated with malignant behavior in GC. Induction of PLOD2 in GC cells under hypoxia PLOD2 expression was reported to be inducible by HIF-1a under hypoxic conditions. We analyzed PLOD2 expression levels in PLOD2 low HSC58 cells after exposure to 21% or 0.5% O 2 for 48 hr, to determine that hypoxia can influence GC cell phenotype under hypoxic condition. We confirmed that expressions of HIF-1a and PLOD2 were induced by hypoxia (Fig. 4a) . It has also been confirmed that PLOD2 expression correlated with HIF-1a expression by immunohistochemistry (j 5 0.68, Supporting Information Fig. S4a ) and qRT-PCR (Supporting Information Fig. S4b) . Next, we evaluated alteration of malignant behavior in HSC58 cells from normoxia to hypoxia. Hypoxic conditions induced PLOD2 overexpression and promoted invasiveness (Fig. 4b) and migration ( Fig. 4c ) in HSC58 cells. To confirm those results in other cell lines, we select NUGC3, a PLOD2 low GC cell line. We also cultured NUGC3 in 0.5% O 2 , resulting in induction of PLOD2 expression, as seen in HSC58 cells' overexpression of PLOD2 (Fig. 4d) . Hypoxia promoted invasiveness and migration as in HSC58 cells (Fig. 4e and 4f ).
PLOD2 expression promotes invasiveness and migration in GC cells, independent from HIF-1a
As previous reported, PLOD2 expression was regulated by HIF-1a in hypoxia condition. HIF-1a has also been reported to induce many genes' expression and affect cancer phenotype. Therefore, it is important to prove that PLOD2 induce malignant behavior independently from HIF-1a expression.
To examine whether PLOD2 independently promoted invasiveness and migration GC cells, we silenced PLOD2 in HSC58 under hypoxic conditions (0.5% O 2 , 48 hr). We confirmed that PLOD2 expression was suppressed by siRNA, and HIF-1a was induced in HSC58 cells under hypoxic conditions, using real-time qRT-PCR and western blotting (Fig.  5a ). To verify their functions in HSC58 cells, we examined cell proliferation, invasiveness and migration. Although proliferation was not influenced in HSC58 cells with siPLOD2, invasiveness and migration were reduced, despite increased HIF-1a under hypoxic conditions (Fig. 5b, 5c , and 5d). These findings thus show that the effects of PLOD2 on invasiveness and migration did not depend on HIF-1a expression. 
Discussion
As several clinical trials have attempted to improve prognosis in GC patients, 26 its survival rate of has been improving in recent years. However, unresectable or metastatic GC has not been treatable, and median survival at that stage is only 9-10 months. 27 Although several molecules have been reported to promote peritoneal dissemination, which is the most common metastatic or recurrence pattern in GC, no novel molecules were found that could provide potential curative targets 3 . In the present work, we found PLOD2 expression to be associated with peritoneal dissemination, and demonstrated that PLOD2 induced by HIF-1a was significantly associated with the malignant behavior in GC.
Our analysis of clinical samples showed that PLOD2 expression was significantly associated with peritoneal dissemination. We also analyzed the T2-4 tumor group to confirm this trend in advanced cancer; the result demonstrated that PLOD2 expression was related to the poor prognosis (Supporting Information Fig. S5 ), lymph node metastasis and peritoneal dissemination in advanced cancer (Supporting Information Table S4 ). In addition, we performed IHC for PLOD2 using the biopsy or resected samples (n 5 44) of GC patients who had been diagnosed the existence of peritoneal dissemination. In our study, 38 of 44 patients (86%) had PLOD2 high expression. These results also supported the association between PLOD2 and peritoneal dissemination of GC. Reportedly, PLOD2 promotes pulmonary metastasis in sarcoma, 21 intrahepatic metastasis in hepatocellular carcinoma (HCC), 22 and lymph node and lung metastasis in breast cancer. 20 Those results support our present findings that PLOD2 is associated with recurrence of peritoneal dissemination of GC. Multivariate analyses of OS also showed that PLOD2 high expression was associated with poor prognosis. In multivariate analyses of recurrent peritoneal dissemination, PLOD2 high expression was a significant independent predictive factor. Our analysis of clinical data showed PLOD2 to be a very important factor in peritoneal recurrence in GC patients.
In our previous study, we detected some genes in the GDES whose expression was associated with peritoneal dissemination in gastric cancer, 16 and which included some putative oncogenes or tumor suppressor genes. Among these genes, PLOD2 was especially correlated with unfavorable prognosis (p 5 0.0002). 
Molecular Cancer Biology
PLOD2 is one of three lysyl hydroxylases (PLOD1 is responsible for lysine hydroxylation in a-helical or central domains; the substrate specificity of PLOD3 is unclear). 18, 28 Reportedly, PLOD2 overexpression correlates with unfavorable prognosis and metastasis in several types of cancers. In breast cancer and HCC, PLOD2 was reported to promote invasiveness and migration. 20, 22 Indeed, PLOD2 knockdown through siRNA in several GC cell lines suppresses invasiveness and migration in vitro. Our study also demonstrated that hypoxic environments induces PLOD2 overexpression and promotes invasiveness and migration in the multiple GC cell lines. Those results demonstrated that PLOD2 regulates invasiveness and migration in GC remarkably. Furthermore, HSC58 cells treated with siPLOD2 and cultured in a hypoxic environment show suppressed invasiveness and migration compared to cells not treated with siPLOD2 under the same conditions, despite upregulation of HIF-1a.
To our knowledge, this is the first study that shows PLOD2 to promote malignancy in GC. We found that PLOD2 itself promotes GC invasiveness and migration, independently from HIF-1a overexpression. Among the GC patients, the PLOD2 high group had large quantities of collagen in their cancer tissues (Supporting Information Fig. S2b) . In cancer biology, collagens regulate physical and the biochemical properties of the cancer microenvironment, which modulate cancer cell polarity, migration and signaling. [29] [30] [31] Depending on the type of cancer, HIF-1a has been shown to promote the initiating step of collagen cross-linkage by activating PLOD2 in hypoxic cancer cells. 7 Previous studies showed high HIF-1a expression in hypoxic environments induced expression of many genes that crosslink collagen and promote peritoneal dissemination in several types of cancer, including GC. 15, 32, 33 Microenvironments in the abdomen are often hypoxic, and promote cancer cell survival and migration within such spaces. 34, 35 PLOD2 is also essentially a collagen-modifying enzyme. Therefore, extraordinary PLOD2 expression is likely to disrupt ECM structures. Considering these mechanisms, our study suggests that the HIF-1a/PLOD2 pathway regulates GC invasiveness and migration in a collagen-dependent manner.
Our present study has several limitations. First, a larger cohort of patients with advanced GC, including peritoneal dissemination cases, and further analysis are required to verify the clinical significance of PLOD2 expression in GC. Second, we performed only in vitro assays in the present study; further study is necessary to confirm the mechanism in more detail, including other molecular or in vivo assays.
In conclusion, we have shown for the first time that PLOD2 is an important regulator of peritoneal dissemination in GC patients. Our study provides novel insights into the mechanism of GC invasiveness and migration through the tumor environment and might be an attractive target for gastric cancer therapy.
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